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a b s t r a c t
                            
Inﬂuenza causes a signiﬁcant burden of disease each year in England and Wales, with the young and
the elderly suffering the greatest burden. Children are recognised as playing an important role in the
dissemination of the inﬂuenza virus. This study examines the population impact of implementing a
programme of paediatric vaccination.
A dynamic transmission model was used to simulate the impact of vaccination programmes with vary-
ing levels of coverage across pre-school and school age children. These analyses suggest that vaccinating
as few as 50% of 2–18 year olds could result in a substantial reduction in the annual incidence of inﬂuenza
related morbidity and mortality across the population. Herd immunity may extend this protection to the
young and the elderly. It is assumed that such programmes would be implemented in concert with the
current strategy of vaccinating the elderly and younger at risk groups with an inactivated vaccine.
In England and Wales, paediatric vaccination of two to eighteen year olds reduced the estimated num-
IV
ndirect protection
erd immunity
ber of general practice consultations, hospitalisations anddeaths arising from inﬂuenzaA andB infections
by up to 95%. This translates into an annual average reduction of approximately 52,000, 1500 and 1200
events, respectively.
A policy of paediatric vaccination could signiﬁcantly reduce the clinical burden of inﬂuenza in England
and Wales, in all age groups, with the added value of herd immunity helping to protect the young and
the elderly who are at highest risk of complications.. Introduction
Inﬂuenza is a highly infectious disease affecting 5–15% of the
verall population worldwide [1] every year, predominantly in the
utumn and winter season in temperate regions. Incidence rates
re highest in children, especially in congregate settings with rates
f up to 50% in children attending day care centres [2]. The bur-
en of inﬂuenza in children is substantial, with frequent primary
are (general practice) consultations in children under the age of 2
ears [3] and in school age children [3,4], as well as a high hospi-
alisation rate in young children [3,5–7]. As children are thought to
e the principal transmitters of inﬂuenza in the community [2,8,9],
dequate childhood vaccination may efﬁciently disrupt the trans-
ission and spread of inﬂuenza in the population, leading to the
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indirect protection (herd immunity) of close household contacts
and of thewider community, including vulnerable risk groupswith
chronic underlying medical conditions and the frail elderly.
Individuals at risk of inﬂuenza related complications include
those with chronic respiratory, heart, liver or kidney disease, and
the immunosuppressed, as well as all individuals over the age of 64
years [10].
Although at risk individuals are currently targeted for seasonal
vaccination in England and Wales and a number of other Euro-
pean countries, vaccination rates in most countries are suboptimal
although coverage of the elderly is often better than that of clini-
cal risk groups [11,12]. A recent survey has shown that vaccination
rates in the elderly differ considerably across Europe [12], being
highest in the UK (70.2%) and lowest in Eastern European countries
such as Poland (13.9%). Furthermore, evidence is accumulating that
vaccination of the elderly with an inactivated vaccine offers only
partial protection. Reported estimates of vaccine effectiveness vary
widely in the elderly, ranging from 20% to over 50% [13,14].
Vaccination rates in individuals with a chronic medical condi-
tion considered at a high risk of developing complications due to
inﬂuenza are also low, ranging from56% in the UK to 11% in Poland.
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Fig. 2. The structure of the age stratiﬁed inﬂuenza SEIRS model. These compart-ig. 1. Who  Acquires Infection From Whom (WAIFW) matrix for Great Britain, as
erived by the POLYMOD study [16] for both physical and non-physical contacts.
accination rates have increased marginally over the last few years.
on-vaccinated individuals constitute a hard to reach group. In
hose EU member states where vaccination rates are low due to
he absence of funding, childhood vaccination may  be an attractive
ption. Provided adequate coverage is achieved, not only will chil-
ren be protected but herd immunity could offer protection to at
isk groups across the age ranges.
. Aims and objectives
The  aim of this paper is to estimate the potential clinical impact
f paediatric inﬂuenza vaccination in England and Wales. Speciﬁc
bjectives were to develop a demographic model of England and
ales, to capture the population structure over time, and to cre-
te a dynamic transmission model simulating the transmission of
nﬂuenza and the current inﬂuenza vaccination policy. A set of risk
unctions were developed to translate the incidence of infection
nto clinical outcomes. The resulting model was  used to estimate
he impact of vaccinating pre-school and school aged children with
 live attenuated inﬂuenza vaccine. Clinical impact was  quantiﬁed
s the mean annual number of averted inﬂuenza infections and the
elated general practice consultations, hospitalisations and deaths,
ver a 15-year time horizon.
.  Methods
.1. Demographics and age dependent mixing
The model adopts a realistic age structure (RAS), starting with
opulation data for England and Wales in 1980, provided by the
fﬁce for National Statistics (ONS). These data are single year of age
tratiﬁed population numbers [15]. Individuals within the model
re aged on a monthly basis. Mortality from causes other than
nﬂuenza starts from age 65 and thereafter is assumed to be a con-
tant risk, corresponding to a mean life expectancy of 25 years for
ndividuals aged 65 (Table 1).
Individuals in different age groups mix  with one another as
eﬁned in a UK speciﬁc age stratiﬁed contact matrix developed by
he POLYMOD study [16]. Such matrices are usually referred to as
Who Acquires Infection from Whom’  (WAIFW) contact matrices
Fig. 1) and provide a relative measure of the frequency of contact
etween individuals of different or similar ages.ments  represent the infection status of the population and do not relate to clinical
presentation.  Infected individuals may  or may not be symptomatic.  a is the age
dependent rate of vaccination. See Table 1 for a list of the remaining parameters.
3.2. Dynamic transmission model
An inﬂuenza transmission model was developed, building on an
approach set out previously [17]. For the purposes of this model,
inﬂuenza is assumed to occur as two  sub-types of inﬂuenza A (e.g.
H1N1 and H3N2) and as inﬂuenza B. All subtypes are assumed to be
immunologically distinct and to occur every two years, with the A
subtypes alternating to give an annual peak in incidence between
week 40 and week 20 of the following year.
The dynamic transmission model subdivides the population into
5 subgroups, the Susceptible, Exposed, Infectious, Recovered and
Vaccinated populations (Fig. 2). This stratiﬁcation is based on the
inﬂuenza virus infection status of members of the population and
not on clinical presentation. A set of linked differential equations
(see Appendix A) describes the ﬂow of individuals between these
subgroups and the system is solved numerically using a fourth
order Runge–Kutta method with adaptive step control [18].
Exposed  (latently infected) individuals are assumed to be
infected for an average of 2 days before becoming infectious [19].
They remain infectious on average for a further 2 days [19], during
which time the intensity and duration of viral shedding is assumed
to be uniform across the age bands.
Once an individual has recovered from infection, they are
assumed to be immune to reinfection with the same subtype. This
immunity wanes over time as a result of the combined effects of
a gradual decline in immunological memory and antigenic drift
on the part of the virus. The resulting duration of protection was
assumed to last for 6 and 12 years for inﬂuenza A and inﬂuenza B,
respectively [17].
3.3.  The basic reproductive rate
The basic reproductive rate (R0) is deﬁned as the number of sec-
ondary infections arising from one primary infection in a totally
susceptible population [20,21]. Using data from past pandemics, R0
for inﬂuenza has been estimated to range from 1.6 to 3.9 [22,23]. A
value for the transmission coefﬁcient was chosen, corresponding to
a  conservative R0 of 1.8, calculated using the dominant eigenvalue
of the next generation matrix [24,25].
3.4. Seasonality
The incidence of inﬂuenza follows a marked seasonal pattern.
Peak incidence was assumed to occur on December 22 and to reach
a minimum on June 23. The magnitude of the basic reproduction
number at the peak of inﬂuenza incidence compared to baseline
was set to 1.43 [17].
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Table  1
Outline of the parameters used in the transmission model.
Parameter Value Source/comment
Transmission coefﬁcient
ˇa,a′
3.99 × 10−08 Chosen to give a mean R0 of 1.8 [22]
Mean duration of latency
1/
2  days Based on volunteer challenge studies [19]
Mean  duration of infectiousness
1/
2  days Based on volunteer challenge studies [19]
Mean  duration of natural immunity
1/ωi
Inﬂuenza A: 6 years
Inﬂuenza  B: 12 years
The duration of protection is likely to be variable. These values are consistent
with the observed dynamics of inﬂuenza and are consistent with those used by
Vynnycky et al. [17]
Mean duration of vaccine induced
immunity
1/ωv
Inﬂuenza A: 6 years
Inﬂuenza  B: 12 years
Assumed to be equal to natural immunity, unless stated otherwise
Seasonal forcing 1.43 The maximum factor by which R0 differs from the mean [17,52]. Assumed to
be sinusoidal, see text
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Coverage rates for LAIV of 10%, 50% and 80% were explored in
each scenario. It was assumed that in those age groups targeted for
paediatric vaccination, LAIV was  used exclusively, with TIV vacci-
nation of at risk individuals in the rest of the population remaining
Table 2
The  percentage efﬁcacy [13,31,32] and uptake of TIV in England and Wales assumed
by  the model (Health Protection Agency data, www.HPA.org.uk, accessed 22nd
January 2010).
Age groups in model % Efﬁcacy % Uptake in total
population
0–<1 60% 0.1%
1–<2  60% 0.1%
2–<5  60% 1.4%
5–<11  60% 1.4%Annual birth rate 621,300/year 
Inﬂuenza independent mortality rate
a
0 for age < 65 years
1/25 years for age > 64 years
.5. Imported inﬂuenza
In  order to capture the inﬂuenza dynamics that are observed in
ngland and Wales, the model population had to be seeded each
ear with new infectious inﬂuenza cases [17]. Annually a total of
00 cases were introduced into each one year age band between the
ges of 5 and 50 years. Children under 5 years old are less likely to
e the ﬁrst individuals infected in an epidemic [26]. Adults over 50
ears of age also tend not to be the ﬁrst infected, due to pre-existing
mmunity to circulating strains.
.6. Model validation
As  a check for coding errors and of the model’s structure and
umerical solution, the RAS model was independently recoded as
 set of partial differential equations (PDEs) and run using the
aseline set of parameter values for inﬂuenza A. Firstly, numeri-
al solutions of the RAS model and the PDE model were compared
isually. Secondly, the PDE model population was  assumed to mix
n a homogeneous fashion and the model was integrated over age
o derive an ordinary differential equation (ODE) system in time
nly. An equilibrium analysis was performed on the ODE system
nd the numerical solution was compared with that of the PDE sys-
em integrated over time. Thirdly, the PDE model was  considered
t the time-independent equilibrium, resulting in a set of ODEs in
ge. This system was solved numerically and compared with the
quilibrium age proﬁle generated from the full PDE system. The
etails of this analysis are included in Appendix B.
The  simulated age stratiﬁed proportion of the population
nfected was checked for face validity against corresponding data
rom the Tecumseh study performed in 1978 [27,28]. The Tecum-
eh data should only be considered as a rough guide as the data are
ld and probably underestimate the proportion infected, especially
n young children [27]. Additionally, population density and mixing
atterns are likely to have changed over the intervening years.
.7.  Risk functions and clinical outcomes
In order to translate incident infections into clinical outcomes,
he model was used to estimate the mean annual number of new
nﬂuenza infections, prior to the introduction of any new interven-
ions. An estimate of the annual number of each clinical outcome
as taken from a previous study of the burden of inﬂuenza [3].
ividing the mean annual number of each outcome by the mean
nnual number of infections provided an age stratiﬁed estimate
f the probability of a new infection leading to a general practice
onsultation, hospitalisation or death.Number of live births per year [15]
Assumed to be zero up to the age of 64. Thereafter, is assumed to be constant
[53]
The  burden of inﬂuenza was  measured using the age stratiﬁed
mean annual number of general practice consultations, hospital-
isations and deaths over 15 years, from 2009 to 2024 (Appendix
A).
3.8. Current practice
Current  practice in England and Wales involves vaccinating
everyone over the age of 65 years and anyone between 6 months
and 64 years of age in a deﬁned risk group [29] with a trivalent
inactivated vaccine (TIV). This policy was introduced in 2000.
Vaccine  induced immunity was assumed to last for the same
duration as natural immunity, with successfully vaccinated indi-
viduals transferring directly from the susceptible to the vaccinated
subgroup. Vaccination was  assumed to have been completed annu-
ally by August 31. Simulated coverage rates (the proportion of the
population vaccinated) were based on data published by the Health
Protection Agency for England and Wales [29,30]. The efﬁcacy of TIV
was  based on prior publications [13,31,32] (Table 2).
3.9.  Impact of paediatric vaccination
Paediatric vaccination scenarios were constructed combining
current practice with strategies to immunise, with a live attenu-
ated inﬂuenza vaccine (LAIV), pre-school age children, aged 2–4
years old, on their own  or in combination with school age children,
aged 5–18 years old. The efﬁcacy of LAIV in children from 2 to 18
years of age was assumed to be 80% [32,33].11–<19  60% 1.4%
19–<50  75% 5.6%
50–<65  75% 5.6%
65+ 50%  73.5%
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Fig. 3. Age distribution of the population of England and Wales in mid 2007, as esti-
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Oated by the Ofﬁce for National Statistics (http://www.statistics.gov.uk/,  accessed
9th May  2010) and by the RAS model used in this analysis.
nchanged. The impact was quantiﬁed in terms of the mean annual
umber of averted incident infections, general practice consulta-
ions, hospitalisations and deaths, over 15 years from 2009 to 2024.
.10. Sensitivity analyses
A  one-way sensitivity analysis was performed on the key param-
ters in the model. Brieﬂy, the impact of varying these parameters
n the cumulative incidence of infection per 100,000 population
etween 1995 and 2020 was estimated, assuming current practice
ombined with 80% LAIV coverage of children from 2 to 18 years of
ge.
The parameter variations were:
the  removal of seasonal forcing
annual  seeding reduced from 100 to 10 infections per year class
R0 values of 1.4 and 2.2
Homogeneous  mixing, maintaining an R0 of 1.8 by adjusting the
transmission  coefﬁcient
Homogeneous mixing, leaving the transmission coefﬁcient
unchanged
Mixing based on the “physical contact only” UK POLYMOD matrix,
rather  than the “all contacts” matrix, maintaining an R0 of 1.8 by
adjusting  the transmission coefﬁcient
Mixing  based on the “physical contact only” UK POLYMOD matrix,
rather  than the “all contacts” matrix, leaving the transmission
coefﬁcient unchanged
Allowing  vaccination to start on 1st September and gradually
increase, achieving the ﬁnal coverage level on the 16th December
The  duration of vaccine induced immunity reduced to half that
of  natural immunity
In addition to the one-way sensitivity analysis, two alternative
cenarios were examined, along with a multi-way extreme value
nalysis and a simulation to explore the impact of a mismatched
accine year. Full details are given in Appendix A.
.  Results
.1. DemographyThe simulated England and Wales population size and age struc-
ure over 30 years, taking the population in 1980 as a starting point,
as seen to increase and age in line with population data from the
fﬁce for National Statistics (Fig. 3).0 (2012) 1208– 1224 1211
4.2.  Temporal dynamics of infection
The simulated impact of current practice, introduced in 2000,
on the quarterly incidence of inﬂuenza (Fig. 4) produces an initial
fall in incidence followed by a partial rebound to a stable cycle with
annual peaks below those prior to the introduction of the new pol-
icy. This is observed with both inﬂuenza A and B, and is consistent
with the observed dynamics of laboratory conﬁrmed inﬂuenza.
The  simulated introduction of paediatric vaccination in 2009
produces a further reduction in incidence that is more pronounced
at higher levels of vaccination coverage and for inﬂuenza B.
The  annual incidence of inﬂuenza A exceeded that of inﬂuenza B
and vaccination at a given level of coverage had a greater impact on
the incidence of inﬂuenza B, than inﬂuenza A. Both these observa-
tions are consistent with the longer duration of natural immunity
to B.
The consequence of each paediatric vaccination scenario, rel-
ative to current practice, can be summarised by the mean annual
number of averted inﬂuenza infections, over the 15-year time hori-
zon of the model.
4.3.  Averted infections
Targeting  two to eighteen year olds, the mean annual numbers
of averted incident infections of inﬂuenza A over the 15 years of
model simulation were 1.6 million, 4.3 million and 4.9 million at
coverage rates of 10%, 50% and 80% respectively. These represent
a percentage reduction of 32%, 84% and 96% respectively. The cor-
responding ﬁgures for inﬂuenza B were 0.67 million (56%), 0.97
million (81%) and 1.1 million (90%).
Targeting paediatric vaccination at the more restricted age range
of pre-school age children (2–4 years of age) at a coverage rate of
80% reduced the mean annual incidence by 1.8 million (36%) and
0.8 million (64%) for inﬂuenza A and B respectively.
Vaccinating 10% of 2–18 year olds is predicted to prevent, on
average, 1 million inﬂuenza A and B infections per year in those
vaccinated, with herd immunity preventing, on average, a further
1.2 million (<2 years: 0.08 million; 19–49 year: 0.8 million; 50–64
years: 0.3 million; 65+ years: 0.07 million) (Fig. 5a).
Increasing vaccination coverage in 2–18 year olds to 50% would
prevent a mean of 2.3 million inﬂuenza A and B infections per
annum in this age group and a further 3 million as a result of indi-
rect protection (<2 years: 0.2 million, 19–49 year: 2 million, 50–64
years: 0.7 million, 65+ years: 0.2 million).
The model suggests that only modest additional gains would be
made by further increasing vaccine coverage to 80% in 2–18 year
olds, preventing an average of approximately 2.4 million inﬂuenza
A and B infections per annum in this age group, with indirect pro-
tection preventing a further 3.5 million infections (<2 years: 0.2
million, 19–49 year: 2.3 million, 50–64 years: 0.8 million, 65+ years:
0.2 million).
A  high level of vaccination coverage (80%) of pre-school age
children aged two to four years is estimated to prevent a similar
number of infections as 10% coverage of 2–18 year olds, with an
annual average of 0.2 million infections prevented in the target age
group and herd immunity averting a further 2.4 million (<2 years:
106,000; 5–18 years: 1 million; 19–49 year: 840,000; 50–64 years:
310,000; 65+ years: 75,000).
4.4.  Progression from infection to clinical outcomes
The predicted probability of an inﬂuenza infection leading to a
general practice consultation was approximately 30% in children
under ﬁve years old. This fell to approximately 10% in ﬁve to sixty-
four year olds, before rising to approximately 50% in people over
sixty-four years of age.
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Fig. 4. The estimated quarterly annual incidence of clinical cases per 100,000 population for inﬂuenza A (left hand panel) and inﬂuenza B (right hand panel). The top row
simulates current practice, with vaccination of risk groups and the elderly with TIV commencing in 2000. The middle row assumes 80% of all 2–4 year olds are vaccinated
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The corresponding predicted probabilities for hospitalisations
how a similar pattern, with children under the age of ﬁve years
xperiencing a higher annual risk than in individuals who  are ﬁve to
ixty-four years old; 0.7% in children under ﬁve years old vs. 0.002%
n those ﬁve to ten years old, rising to 0.2% in adults who  are ﬁfty
o sixty-four years old. The annual probability of hospitalisation is
ighest in those over sixty-four years old, at approximately 8%.
The predicted probability of infection leading to death was
nder 0.001% in children under eleven years of age, rising to
pproximately 0.07% in ﬁfty to sixty-four year olds. The correspond-
ng risk of death increased considerably in the over sixty-four year
lds, to approximately 9%, although the greater part of this risk is
ikely to be concentrated in the oldest individuals.
.5. Averted clinical outcomes
Paediatric  vaccination of two to eighteen year olds, at cover-
ge rates of 10%, 50% and 80%, reduced the simulated mean annual
umber of general practice consultations resulting from inﬂuenza A
nd B infections in the entire population by 310,000 (37%), 690,000
84%) and 790,000 (95%) respectively. Corresponding ﬁgures for
ospitalisations were 8000 (34%), 19,000 (78%) and 23,000 (94%)
nd for deaths were 6000 (33%), 15,000 (76%) and 18,000 (94%).
An  80% coverage of 2–4 year olds reduced the mean annual
umber of consultations, hospitalisations and deaths in the entire
opulation by 360,000 (44%), 10,000 (40%) and 7000 (36%).xpanded to cover 2–18 year olds, with the same 80% coverage rate with LAIV from
Vaccinating 10% of two to eighteen year olds is predicted to
avert an annual mean of 140,000 general practice consultations in
this age group and a further 160,000 in the wider population, as a
result of indirect protection (<2 years: 25,000; 19–49 years: 75,000;
50–64 years: 25,000; 65+ years: 36,000) (Fig. 5b).
Increasing coverage of 2–18 year olds to 50% signiﬁcantly
increases  the mean annual number of consultations averted, with
310,000 prevented by vaccination in the target age group and
herd immunity preventing 390,000 more (<2 years: 56,000; 19–49
years: 187,000; 50–64 years: 60,000; 65+ years: 82,000).
Further increasing the coverage to 80% of 2–18 year olds results
in diminishing returns reﬂecting the pattern of infection, annu-
ally preventing a mean of 330,000 consultations in those age
groups receiving the vaccine and herd immunity averting 463,000
additional consultations (<2 years: 63,000; 19–49 years: 223,000;
50–64 years: 74,000; 65+ years: 103,000).
The corresponding ﬁgures for 10% coverage of 2–4 year olds
were 185,000 consultations prevented in the targeted age groups,
with indirect protection averting a further 180,000 (<2 years:
32,000; 19–49 years: 80,000; 50–64 years: 28,000; 65+ years:
39,000).
The skewed nature of the probability of hospitalisation or death
with age, once infected with inﬂuenza, is apparent in the number
of these outcomes averted by paediatric vaccination.
Within those age groups targeted, vaccination of 10% of 2–18
year olds is estimated to prevent an annual mean of approximately
R.J. Pitman et al. / Vaccine 30 (2012) 1208– 1224 1213
Fig. 5. (a) The estimated mean annual number of averted infections between 2009 and 2023 by age group, relative to current practice. The ﬁrst three panels illustrate the
impact, on inﬂuenza A and B, of vaccinating 2–18 year olds with LAIV, at coverage rates of 10%, 50% and 80% respectively. The ﬁnal panel illustrates the impact of targeting the
more  restricted age range of 2–4 year olds with LAIV at an 80% coverage rate. (b) The estimated mean annual number of averted General Practice consultations between 2009
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000 hospitalisations (Fig. 5c) and fewer than 20 deaths (Fig. 5d).
erd immunity in the remaining population would prevent 7300
ospitalisations and 6500 deaths, of whom 5400 (74%) and 6100
95%) respectively are in the elderly over 64 years of age.
At  50% coverage of 2–18 year olds, the model predicts that 2400
ospitalisations and approximately 40 deaths per year would be
revented in the targeted age groups, with indirect protection in
he remaining population averting a further 16,800 hospitalisations
nd 14,700 deaths of whom 12,300 and 14,000 respectively are in
he elderly.
Vaccinating 80% of 2–18 year olds is estimated to prevent 2600
ospitalisations and 40 deaths in those targeted and to indirectly
vert 20,700 hospitalisations (15,400 in 65+ year olds) and 18,400
eaths (17,500 in 65+ year olds).
.6. Validation
The PDE model produced simulations of the temporal dynam-
cs of infection and the equilibrium age distribution that were very
lose to those generated by the ODE model (Appendix B for full
etails). Exact correspondence would not be expected, as the mod-
ls are structurally different.
The pattern in the proportion of the population that is infected
y age is consistent with that observed in the Tecumseh studies in
he 1970s [27], particularly for inﬂuenza A (Fig. 6a). The simulated
eak incidence of inﬂuenza B in school aged children corresponds
ell with these data, however, in the older age classes the modelure a. (c) The estimated mean annual number of averted hospitalisations between
t ﬁgure a. (d) The estimated mean annual number of averted deaths between 2009
re a.
predicts  a prevalence of infection that is approximately 5% higher
than the Tecumseh data (Fig. 6b).
4.7. Sensitivity analysis
The  sensitivity analysis outlined in Appendix A demonstrates
that, while the number of averted case is inﬂuenced to varying
degrees by changes in the parameter values, the qualitative results
are robust, with paediatric vaccination likely to result in a substan-
tial number of averted primary care consultations, hospitalisations
and deaths.
5.  Discussion
This study builds on previous inﬂuenza transmission modelling
[17] which examined the potential impact of paediatric inﬂuenza
vaccination on the incidence of disease and mortality in England
and Wales but did not formally analyse or quantify the potential
implications for GP consultations, hospitalisations and deaths. The
concepts drawn from that paper were the use of waning immunity
to simulate antigenic drift and the annual seeding of the population
with new infectious individuals.
This  manuscript extends the analysis to look at the impact
of paediatric vaccination on clinical outcomes: GP consultations,
hospitalisations and deaths, and encompasses both the trivalent
inactivated vaccine and a live attenuated vaccine that has recently
been licensed for use in Europe.
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Fig. 6. (a) The observed proportion of the population infected with inﬂuenza A in Tecumseh 1967–8 [27] and as predicted by the RAS model. A1 refers to a single inﬂuenza A
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977–8 [27] and as predicted by the RAS model.
This analysis demonstrates that paediatric inﬂuenza vaccina-
ion has the potential to signiﬁcantly reduce the clinical burden
f inﬂuenza in England and Wales. The estimated proportion of
nfections prevented across the entire population is consistent with
revious modelling estimates [17,34].
Children under the age of 5 years, and in particular those under
 years, experience the highest annual rate of general practice
onsultations and hospitalisation per 100,000 population [3] and
herefore stand to beneﬁt from a programme of paediatric vaccina-
ion, even if they themselves are not vaccinated.
Children are believed to be efﬁcient transmitters of the virus,
or a number of reasons [2,8,9]. There is some evidence for more
ntense and prolonged shedding of the virus in children [35,36] and
or frequent contacts between children and between children and
dults [16]. Disrupting this transmission by vaccinating children
ay have the additional effect of protecting the wider community
hrough the indirect protection offered by herd immunity [37,38].
The  simulated effect of indirect protection is apparent in, for
xample, the age stratiﬁed number of averted inﬂuenza infections
Fig. 5a). Where pre-school and school age children are vaccinated,
he model suggests that the greatest number of averted infections
s in the 19–49 year old age class, consistent with available data
39]. Averted infections are predicted in all age classes, including
he very young and the elderly who are at greatest risk of hos-
italisation and death. This is further reﬂected in the number of
eneral practice consultations, hospitalisations and deaths avoided
cross the age ranges, with the elderly in particular protected from
ospitalisation and death. It is of note that these gains would be
chieved by targeting an age group (2–18 year olds) that make up
pproximately 20% of the population.
The greatest increase in the number of infections averted occurs
hen increasing coverage from 10% to 50%, suggesting that higher
ates of coverage may  produce diminishing returns. This is espe-
ially true when the target age range is restricted. An 80% coverage
f 2–4 year olds results in a comparable number of averted cases
o 10% coverage of 2–18 year olds.
The quantitative details of the simulations were found to vary
epending on the parameter values chosen, particularly the value
f those parameters with a direct bearing on the basic repro-
uctive rate, such as the transmission coefﬁcient and the age
tratiﬁed pattern of population mixing. The qualitative pattern was,
owever, robust, with the largest number of primary care consul-
ations averted in 19–49 years olds, as well as in children over one
ear of age and the elderly. Paediatric vaccination is estimated to
revent up to 95% of hospitalisations and deaths resulting from
nﬂuenza, 74% and 95% of which, respectively, occur in the elderly.
s infections that lead to hospitalisation are those with the highest) The observed proportion of the population infected with inﬂuenza B in Tecumseh
level  of morbidity and have the greatest impact on the health
service, the indirect effects of vaccination have the potential to
inﬂuence the overall effectiveness and cost-effectiveness of a pae-
diatric vaccination programme. The cost-effectiveness of paediatric
vaccination strategies will be addressed in a separate paper.
There  has been some debate as to the strength of the indi-
rect protection effects associated with inﬂuenza vaccination [40],
however a recent randomised controlled study to quantify these
effects has been completed in 3273 children of 36 months to 15
years of age in 49 Hutterite colonies in Alberta, Saskatchewan,
and Manitoba, Canada [41]. A total of 947 were vaccinated against
inﬂuenza using TIV and 2326 community members received a hep-
atitis A vaccination as a control. At a mean TIV coverage rate of
83% (range, 53–100%), indirect protection of non-recipients of the
inﬂuenza vaccine had a protective effectiveness of 61% (95% conﬁ-
dence interval, 8–83%; P = .03). The overall protective effectiveness
(direct and indirect protection) was  estimated to be 59% (95% CI,
5–82%; P = .04). Bearing in mind that this randomised controlled
study was  over a single season, used TIV rather than LAIV and
targeted a slightly narrow age range, the estimate of indirect pro-
tection is consistent with that estimated in this paper.
The  long-term impact of vaccination on the dynamics of
inﬂuenza transmission depends in part on the degree of cross pro-
tection between different strains, imparted by the vaccine. This
analysis has highlighted the potential importance of herd immunity
in preventing inﬂuenza in high risk groups. A long-term pro-
gramme  of vaccination may, however, alter the breadth of this herd
immunity.
The inﬂuenza virus evolves away from the herd host immune
protection by a process of antigenic shift and drift [42,43]. Each indi-
vidual host immune system comprises a repertoire of immunities
to strains that had previously infected that individual. This natu-
ral immunity is long term and has some level of cross-protection
against strains not previously experienced by that individual.
Thus the natural herd immunity of a population is based on the
collective experience of inﬂuenza over the last 50 years and is
cross-protective to varying degrees against other related strains
as well.
It  can be assumed that vaccine induced immunity is less
cross-protective and possibly shorter lived than natural immunity,
although studies of the duration of immunity in naturally exposed
individuals and from time series data have proved inconclusive
[44,45]. If an effective seasonal inﬂuenza vaccination strategy were
in place for 50 years, the herd immunity of the population will com-
prise the collective experience of annual inﬂuenza vaccination over
the last 30 or so years (as the immunity from 30 to 50 years will
have waned and natural infection would have been rare). This new
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he  estimated 74,295 averted by vaccinating 80% of all 2–18 year old children with 
erd immunity will be at a high level, but its antigenic scope may
e narrower than the natural herd immunity counterpart, possibly
eading to an increased susceptibility to strains that have under-
one antigenic drift or shift.
Strains that have undergone antigenic shifts have the poten-
ial to cause pandemics, as was observed in 2009. These emerging
trains typically infect and cause morbidity in younger individu-
ls than those responsible for seasonal inﬂuenza [46,47]. With the
mergence of A(H1N1)v following the 2009 pandemic, this shift
n the age distribution of infection towards younger individuals is
ikely to increase the direct beneﬁts of paediatric vaccination.
The  temporal dynamics of inﬂuenza infection further illustrate
he need to assess inﬂuenza vaccination strategies over an extended
ime horizon. Following the introduction of a new programme of
accination, the incidence of infection would be expected to follow
 well recognised pattern [48,49]. There is an initial drop in inci-
ence, called the honeymoon period, brought about by the addition
f protection arising from immunisation to the existing naturally
cquired immunity. The resulting fall in incidence leads to a reduc-
ion in naturally acquired immunity, allowing a partial rebound.
nfection incidence then settles into a new suppressed cycle. This
attern is consistent with the observed pattern of laboratory con-
rmed inﬂuenza in England and Wales.
While the temporal pattern of inﬂuenza incidence is consis-
ent with the available observed data, the lack of recent population
ide data on infection incidence and prevalence is a limitation to
odelling inﬂuenza transmission. The collection of good quality
opulation level data on the incidence and prevalence of inﬂuenza
nfection would help to reduce uncertainty when calibrating such
odels. However, alternative analyses of the impact of vaccination
olicies, which fail to account for the dynamic nature of transmis-
ion, risk seriously underestimating the potential effects of such
olicies.
A further weakness in the model is the inconclusive nature of
ata on the duration of vaccine induced immunity as well as on
hat arising from natural infection. Should the duration of vaccine
nduced immunity be signiﬁcantly shorter than its naturally arising
ounterpart, then the impact of paediatric vaccination would be
educed.
While multiple studies have shown the indirect beneﬁt (herd
mmunity) in adults through vaccinating children against inﬂuenza
41,50,51], each of these studies used different study designs result-
ng in variability in the estimated beneﬁts. Additional studies
omparing real world dynamics of inﬂuenza transmission against
ynamic models are of interest.pulation, from 2009 to 2020, to changes in the model parameter values, relative to
n addition to current practice.
This analysis demonstrates the complex and inter-related
nature of factors inﬂuencing the evaluation of paediatric inﬂuenza
vaccination. While there remains uncertainty in many of the
parameters, the qualitative picture emerging suggests that paedi-
atric vaccination may  result in substantial beneﬁts to children, as
well as to those at risk of inﬂuenza related complications and to the
elderly.
Appendix A.
A.1.  Demography
Underlying this analysis is a realistic age structured (RAS) demo-
graphic model that simulated the population of England and Wales
from 1980 through to 2024. The starting data derives from national
population statistics, collated by the Ofﬁce for National Statistics
(ONS, http://www.statistics.gov.uk/,  accessed 6th January, 2009).
Individuals are born and the population is aged at the end of
each month:
Pm = 51, 775 for m = 0
Pm = Pm−1 for m = 1–1200 months
where Pm is the number of individuals of age m (in months) in the
population.
Natural mortality attributed to all causes other than inﬂuenza
is applied as a continuous function:
dPa
dt
= aPa(t)
for a = 0–65 years, a = 0
for a = 66–100, 1/a = 25
A.2.  Transmission model
The  dynamic transmission model compartmentalises the
population solely on the basis of individual’s age and their immuno-
logical and inﬂuenza infection status. These compartments are
composed of Susceptible, Exposed (latently infected), Infectious,
Recovered and Vaccinated individuals. It is assumed that a pro-
portion, that is less than 100%, of infectious individuals are
symptomatic and that all symptomatic individuals are at some
point infectious.
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he  estimated 17,220 averted by vaccinating 80% of all 2–18 year old children with 
The ﬂow of individuals between each of the compartments,
ncluding the dynamics of inﬂuenza transmission, progression and
ecovery, are described by the following set of linked differential
quations, for a = 0, 1, 2, . . .,  100 years of age:
dSa
dt
=  ωvVa(t) + ωiRa(t) − Sa(t)[a + a + a(t)]
dEa
dt
= a(t)Sa(t) − Ea(t)[a + ]
dIa
dt
= Ea(t) − Ia(t)[a + ]
dRa
dt
=  Ia(t) − Ra(t)[a − ωi]
dVa
dt
= aSa(t) − Va(t)[a + ωv]
here ωv and ωi are the rate of loss of vaccine induced and nat-
rally acquired immunity respectively. The natural death rate is
iven by a, the average latent period by 1/ and the duration of
nfectiousness as 1/. The age dependent vaccination rate is signi-
ed by a and a(t) represent the age dependent force of infection
n the model
a(t) = z(t)
∑
a′
ˇa,a′ Ia′ (t)
here  ˇa,a′ is the transmission coefﬁcient describing the rate of
ontact and probability of transmission from individuals of age a′
o those of age a. The term z(t) is a sine wave function emulating
he seasonal ﬂuctuation in the force of infection:
(t) = 1 + q · sin
(
2(t − p)
365
)
here t is the number of days since the start of the simulation, q
ontrols the amplitude and p the phase of the wave.
These ﬁrst order ordinary differential equations were numer-
cally solved using a fourth-order Runge–Kutta method with
daptive step control [18].
The  dynamic transmission model was programmed in Fortran
nd the outputs saved in comma  delimited text format for subse-
uent import into Microsoft Excel for graphical presentation.
.3.  Averted infectionsThe  number of infections averted by the instigation of a pro-
ramme  of paediatric vaccination was used as the basic outcome
easure from the dynamic transmission model.pulation, from 2009 to 2020, to changes in the model parameter values, relative to
n addition to current practice.
The  incidence of inﬂuenza A infection for age group i on day d,
zdi, is given by
zdi =
∫ T+1
T
j′∑
a=j
a(t) · Sa(t)dt
that is the sum of incident cases from time T at the start of day
d to the start of the following day at time T + 1, in age group i that
encompasses the years of age, a, from j to j′. The number of incident
cases of age a, at time t, is the product of the force of infection, a
and the number of susceptible individuals, Sa.
The total number of incident cases, Zi in age group i between the
1st January 2009 (d = 10,585) and 31st December 2023 (d = 16,059)
was calculated as
Zi =
16,059∑
d=10,585
zdi
Let the total incident cases by age group under the current prac-
tice be Zi and the corresponding number in an alternative scenario
be Zi ′.
The averted number of infections in age group i, Ai is therefore
Ai = Zi − Z ′i
Corresponding ﬁgures were calculated for inﬂuenza B.
A.4.  Sensitivity analysis
A.4.1.  One way
A  one-way analysis was carried out to establish the sensi-
tivity of the estimated cumulative number of averted cases per
100,000 population, from 2009 to 2020, to changes in the model’s
parameters, when summed over all age groups (Table A1 and
Figs. A1 and A2).
The  effect of seasonal ﬂuctuations in the transmission of the
virus was removed by setting the forcing function to zero, resulting
in a reduction in the number of averted case of 40% and 32% for
inﬂuenza A and B respectively. Reducing the seeding term to 10,
from 100, had relatively little effect on averted cases, reducing the
number of inﬂuenza A cases by 14% and B cases by 5%.Changes in the basic reproductive rate had the greatest impact
on the number of averted cases. Increasing R0 from 1.8 to 2.2
resulted in an increase in the number of averted cases, of approx-
imately 20% and 30% for inﬂuenza A and B, respectively. Reducing
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Fig. A3. (a) Sensitivity of the temporal pattern of incidence to changes in model parameters. The traces on the top row are the reference (standard) and assume 80% LAIV
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soverage of 2–18 year olds. Vaccination of the elderly was  simulated to have com
ensitivity of the temporal pattern of incidence to changes in model parameters as
0 to 1.4 from 1.8 reduced the number of averted cases by approx-
mately 50% in both cases.
The  sensitivity to the value of the basic reproductive rate
s reﬂected in changes resulting from alterations to the pattern
f population mixing. If mixing is assumed to occur randomly
etween individuals of different ages (homogeneous mixing), while
aintaining the same viral propensity to transmit (constant trans-
ission coefﬁcient) then the basic reproductive rate increases to
.35 and the number of averted inﬂuenza A cases falls by 39%. A
imilar effect in the opposite direction is observed for inﬂuenza B,
ith an increase of 44%. If, however, the transmission coefﬁcient
able A1
he  cumulative number of averted inﬂuenza cases per 100,000 population between
009 and 2020, summed over all age groups. See text for a description of the
cenarios.
Averted cases/100,000 population over 12 years
Scenario Inﬂuenza A Inﬂuenza B
80% LAIV vaccination, 2–18 yr olds 74,295 17,220
80%  LAIV vaccination, 2–17 yr olds 73,740 17,076
Homogeneous  mixing (R0 = 1.8) 72,778 14,581
Vaccination  spread 72,525 17,053
Duration  of vaccine protection halved 77,689 19,389
Vaccinate  same people each year 70,406 16,976
Physical  contact matrix (R0 = 1.8) 78,971 21,339
Seed  value 10 64,107 17,999
R0 2.2 89,820 22,665
Homogeneous  mixing (R0 = 4.35) 44,950 24,854
No  seasonality 44,354 11,756
R0 1.4 37,060 9151
Physical  contact matrix (R0 = 1.1) 15,795 4279ced in September 2000 and paediatric vaccination added in September 2009. (b)
g 80% LAIV coverage of 2–18 year olds. See Fig. 3a for reference traces.
is adjusted to maintain an R0 of 1.8, then a more modest fall is
observed in the number of cases averted with both inﬂuenza A and
B (2% and 15% respectively).
If  mixing is based on the “physical contact only” POLYMOD
matrix [16], rather than the “all contacts” matrix, then the number
of averted cases falls by 78% for inﬂuenza A and 75% for inﬂuenza B.
This large fall is predominantly the result of R0 being reduced to 1.1
leading to fewer cases of inﬂuenza. Consequently, there are fewer
cases to prevent. Adjusting the transmission coefﬁcient to maintain
an R0 of 1.8 resulted in an increase in the number of inﬂuenza cases
averted rather than a fall, of 6% for inﬂuenza A and 24% for B.
As  the rate of vaccine uptake in the population may  vary, this
analysis assumes that all vaccinations are delivered before the start
of the inﬂuenza season. Relaxing this assumption to allow for a
more gradual uptake, starting on the 1st September and continuing
to the 16th December made less than a 3% difference to the number
of cases averted.
As  the duration of vaccine induced immunity is often shorter
than that of natural immunity, its duration was reduced to half that
arising from a natural infection. This too produced only marginal
differences in the numbers of cases averted (5% and 13% for
inﬂuenza A and B, respectively).
A.4.2.  Scenario analysis
On  the 1st February 2011, the European Commission granted
marketing authorisation to a nasally administered LAIV, for the pre-
vention of seasonal inﬂuenza in children aged 2–17 years of age. In
order to estimate the impact of reducing the target age range by one
year, the model was  rerun, simulating the vaccination of this tar-
get group and the cumulative number of averted cases per 100,000
1218 R.J. Pitman et al. / Vaccine 30 (2012) 1208– 1224
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see text for details). (b) Simulated distribution of averted inﬂuenza cases per 100,0
nalysis.
opulation over 12 years, calculated in the same way  as for the
ne way sensitivity analysis. This resulted in a fall in the number of
ases averted of 0.7% for inﬂuenza A and 0.8% for inﬂuenza B.
The  model assumes that a random selection of individuals are
accinated each year, however, it is also possible that the same
ndividuals return each year to be vaccinated. Assuming a duration
f vaccine induced protection of 6 years against inﬂuenza A, this
ould result in a reduction in the cumulative proportion of children
rotected from 64% to 40%. Vaccine coverage was lowered to 18%
n the model, to reﬂect this reduction, and the cumulative number
f averted cases per 100,000 population over 12 years calculated as
bove. This resulted in a reduction in the number of cases averted
f 5% and 1% for inﬂuenza A and B respectively.
.4.3. Temporal dynamics
The  impact of these parameter changes on the temporal dynam-
cs of inﬂuenza A and B varied considerably (Fig. A3). Removing
easonal forcing resulted in the dynamics being driven by annual
eeding, a reduction in which led to an increase in the inter-
pidemic period.
Reducing R0 also reduced the peak quarterly incidence of cases.
 higher R0 increased peak incidence and made its reduction viaused by inﬂuenza A, stratiﬁed by R0 and generated by the extreme value analysis
ulation caused by inﬂuenza B, stratiﬁed by R0 and generated by the extreme value
vaccination  harder. Allowing the population to mix  randomly had
a similar effect, resulting from the associated increase in R0, from
1.8 to 4.35. Reducing the transmission coefﬁcient to compensate for
this increase returns the dynamics to a pattern similar to that seen
simulating current practice, except for an extended honeymoon
period.
Basing the mixing matrix on the “physical contact only” POLY-
MOD matrix [16] while constraining R0 to a value of 1.8 had very
little impact on the dynamics of inﬂuenza A. The inter-epidemic
period of inﬂuenza B was increased by vaccinating the elderly, as
was  the peak incidence, however, incidence was suppressed to very
low levels by LAIV.
Allowing  for a more gradual increase in vaccination had lit-
tle effect, as did assuming the same individuals were vaccinated
each year, while halving the duration of vaccine induced immunity
allowed the peak annual incidence of inﬂuenza to increase.
A.4.4.  Extreme value analysis
A  multi-way sensitivity analysis was performed by deﬁning a
low, expected and high value for the key parameters and run-
ning simulations for every possible combination. For n variables
there are 3n combinations. For each combination, an inﬂuenza
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Table  A2
The  estimated effect of a mismatched vaccine on the number of clinical outcomes in the 2015/16 inﬂuenza season, relative to the same season with a matching vaccine.
Matched 2015/16
season
Mis-matched 2015/16
season
Difference
Current practice GP  consultations 793,006 937,376 144,370
Hospitalisations 23,638 30,926 7287
Deaths  18,726 25,686 6959
55,81
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coverage  in 2–18 year olds
GP  consultations 
Hospitalisations 
Deaths  
 simulation was run with and without paediatric vaccination
nd the number of averted cases of symptomatic inﬂuenza calcu-
ated per 100,000 population between 1995 and 2020, assuming
urrent practice combined with 80% LAIV coverage of children
rom 2 to 18 years of age. The procedure was then repeated for
nﬂuenza B. Including all 18 model parameter would have required
18 = 387,420,489 simulations and taken just over 12 years to com-
lete. In order to be achievable, the following parameters were
hosen to vary:
The  transmission coefﬁcient (corresponding to R0 of 1.4, 1.8 and
2.2)
The  number of infectious cases seeded into the population each
year  (50, 100, 150)
The  duration of natural immunity (inﬂuenza A: 5 years, 6 years,
7  years; inﬂuenza B: 11 years, 12 years, 13 years)
The duration of infectiousness (1 day, 2 days, 5 days)
The  percentage of infected individuals that experience symptoms
(55%,  64%, 73%)
The  latent period (1 day, 2 days, 3 days)
The  duration of vaccine induced immunity (Flu A: 3 years, 6 years,
7  years; Flu B: 6 years, 12 years, 13 years)
The  distribution of results for both inﬂuenza A and B (Fig. A4a
nd b) display a high peak at low numbers of cases averted. This
eak corresponds to values of R0 below or close to 1. As a results,
here are few cases of inﬂuenza and so correspondingly few to
revent. As R0 increases to 1.8, so does the mean number and
pread of averted cases. In these simulations, while the virus has the
otential to spread, it is still well controlled by paediatric vaccina-
ion. Once R0 increases above 1.8, inﬂuenza transmission becomes
ncreasingly difﬁcult to control using paediatric vaccination and the
umber of averted cases begins to fall.
At a R0 of 1.8, the base case values of 74,295 and 17,220 averted
ases per 100,000 population for inﬂuenza A and B lie at the lower
nd of the simulated distribution, suggesting that our estimates are
onservative.
.4.5. Mismatched vaccine year
In order to explore the potential impact of a mismatched vac-
ine, two additional simulations were run, in which vaccine efﬁcacy
as assumed to be reduced by a factor of 5/8 during the 2015/16
eason. The ﬁrst corresponded to current practice, vaccinating risk
roups and the elderly with TIV at efﬁcacies of 38% (6 months–18
ears of age), 47% (19–64 years) and 31% (over 64 years). The second
imulated paediatric vaccination, in addition to current practice
ith reduced TIV efﬁcacy as above, with LAIV administered to 50%
f 2–18 year olds at an efﬁcacy reduced by 5/8 to 50% [54,55].
Comparing these simulations of a mismatched vaccine in the
015/16 inﬂuenza season with previous simulations of the same
eason with a matching vaccine, current practice resulted in an
stimated additional 145,000 GP consultations, 7300 hospitalisa-
ions and 7000 deaths. Corresponding ﬁgures for current practice
lus LAIV were 48,000, 2000 and 1800, respectively (Table A2).2 103,624 47,812
5 4087 2092
3 3507 1874
Appendix B.
The  RAS model (as used in the main text) is written as a set of
PDEs and the baseline set of parameter values is used to validate
the model structure and numerical solution. Firstly, numerical solu-
tions of the RAS model and the PDE model were compared visually.
Secondly, the PDE model was  assumed to have homogeneous mix-
ing and was  integrated over age to derive an ODE  system in time
only. An equilibrium analysis was  performed on the ODE system
and the numerical solution was  compared with that of the PDE sys-
tem integrated over time. Thirdly, the PDE model was considered
at the time-independent equilibrium, resulting in a set of ODEs in
age. This system was  solved numerically and compared with the
equilibrium age proﬁle generated from the full PDE system.
B.1.  Parameter set for model veriﬁcation and comparison
A single parameter set was  used for the RAS, PDE and ODE mod-
els for veriﬁcation purposes.
Parameter Units Description
3.99E−08 day−1 Transmission coefﬁcient
−101  Days Offset in days – for seasonality sine wave
100 Count Number of infectious cases seeded into age bands
5–50  each year
6  Years Duration of natural immunity
0.43  None Seasonal forcing
2  Days Infectious period
51,775 Count Live births per year
2 Days Latent period
Annual seeding occurs on the 1st September each year.
B.2. The PDEs
∂S
∂t
+ ∂S
∂a
= ωR(a, t) − S(a, t)[	(a) + (a, t)]
∂E
∂t
+ ∂E
∂a
= (a, t)S(a, t) − E(a, t)[	(a) + ]
∂I
∂t
+ ∂I
∂a
= E(a, t) − I(a, t)[	(a) + ]
∂R
∂t
+ ∂R
∂a
=  I(a, t) − R(a, t)[	(a) + ω]
(a, t) = 

c∑
j=1
[
mij
∫ A(j)
A(j−1)
I(a, t)da
]
for a ∈ (A(i − 1), A(i)), i = {1, . . . , c}
S(0, t) = (t)
	(a) =
0  for 0 ≤ a < 65
1
25
for a ≥ 65
}
where: (t) is the time dependent birth rate of the population; 	(a)
is the age dependent mortality rate; mij are elements of the contact
matrix divided by the element in position (1,1); c is the number
of age categories; 
 is a factor that transforms the contact levels
into transmission rates, A(c − 1) and A(c) are the lower and upper
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a
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ge limits respectively of age class c. The all contacts mixing matrix
16] was used.The  above equations were solved numerically using the esca-
ator boxcar train method [56], written in matlab, to obtain age
istributions varying in time. The PDE model output was  compared
o the RAS model output for a given set of parameters to verify the0 (2012) 1208– 1224
RAS code. The following graphs represent the RAS and PDE model
outputs for no seasonality or annual seeding, seasonality and no
annual seeding, no seasonality but annual seeding and seasonal-
ity and annual seeding respectively. The outputs are similar but
not identical. This is to be expected since the RAS model is not
structurally identical to the PDE model.
No seasonality and no annual seeding:
Seasonality and no annual seeding:
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No seasonality but annual seeding:
Seasonality and annual seeding:
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ODEs in time: The output was compared to the solution of the
omogeneous mixing equivalent set of ordinary differential equa-
ions (ODEs) in time derived from integrating the PDEs with respect
o age to obtain the following equations.
dS
dt
=  N + ω[N − S(t) − E(t) − I(t)] − S(t)[ + (t)]
dE
dt
=  (t)S(t) − E(t)[ + ]
dI
dt
= E(t) − I(t)[ + ]
(t) = ˇI(t)
We  assume homogeneous mixing by giving  ˇ as 
 multiplied
y the mean of mij. There are two equilibria the trivial disease free
quilibrium and the non-trivial disease present equilibrium.
S∗
E∗
I∗
)
=
(
N
0
0
)
or
⎛
⎜⎜⎜⎜⎜⎝
( + )( + )
ˇ
(  + )(ω + )[ˇN − ( + )( + )]
ˇ [( + )(ω + ) + ( +  + ω)]
(ω  + )[ˇN − ( + )( + )]
ˇ [( + )(ω + ) + ( +  + ω)]
⎞
⎟⎟⎟⎟⎟⎠
Jacobean matrix:
−ˇNI∗ − (ω + ) −ω −ˇS∗ − ω
ˇI∗ −( + ) ˇS∗
0  −( + )
⎞
⎟⎠
Deﬁne the basic reproduction number
0 =
ˇN
( + )( + )
The  trivial disease free equilibrium becomes unstable when the
asic reproduction number is greater than unity. An approximation
or the basic reproduction number based on the time independent
DE system and the baseline set of parameter values is 1.5. This
alue is close to that estimated from the RAS model using the next
eneration matrix.
The  following graph represents a comparison between the
DE model output (solid blue) for infectious individuals com-
ared with that produced from a numerical solution of the ODE
ystem in time (dashed red). The outputs are similar but not iden-
ical since the ODE model does not include heterogeneous contacts.0 (2012) 1208– 1224
ODEs in age: The time independent equilibrium age distribu-
tions can be obtained from the full PDE system by equating the
derivatives with respect to time to zero.
Let
X =
⎛
⎜⎜⎜⎝
S∗ (a)
I∗ (a)
E∗ (a)
R∗ (a)
⎞
⎟⎟⎟⎠
and
J(a, k) =
⎛
⎜⎜⎜⎝
−(k) − 	(a) 0 0 ω
(k) − − 	(a) 0 0
0   − − 	(a) 0
0  0  −ω − 	(a)
⎞
⎟⎟⎟⎠
where
(k) = 

c∑
j=1
[
mkj
∫ A(j)
A(j−1)
I(a, t)da
]
Then solve (dX/da) = J(a, k)X to obtain
X(a)  = X(A(k − 1)) exp[J(a, k)(a − A(k − 1))] for A(k − 1)
≤ a ≤ A(k), k = (1, . . . , c)
This is a piecewise solution of a linear system in each age class
using the vector . However the vector  involves a sum over
all ages. Therefore, the distributions X(a) can be obtained by using
an initial guess for , solving the system and recalculating  and
repeating this process until the solution converges.
The following graph shows the equilibrium age distribution
of infected individuals predicted from the PDE model (solid
blue) and the ODE system in age (dashed red). These outputs
should be and are very similar since the method for calculating
this distribution should predict the equilibrium age distribution
of the PDE model with numerical but not structural error, and
within 70 years, the PDE model has visibly reached this equilibrium.
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